Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transgene Loses Roche As A Partner But Stays The Course On Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche backed out of a development deal with Transgene for a therapeutic vaccine, but the French drug developer says the implications, at least for the short term, are minimal.

You may also be interested in...



Cancer Vaccines Headed For Mainstream

No longer the odd cousins of traditional pharmaceutical applications, a host of therapeutic cancer vaccines is working through late-stage trials with real, life-extending data already reported and the potential to create a lot of action in the oncology sector.

Transgene Plans Stock Offering Up To €150 Million And Profitability By 2015

Transgene to raise more capital following the granting of an exclusive option on its lead product to Novartis.

Roche And Transgene Partner On Therapeutic Vaccine For HPV-Related Diseases

Deal has “potential to expand and evolve into an integrated personalized medicine approach” to HPV-mediated diseases, Roche tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel